Cov tshuaj peptide tshiab rau kev tswj cov piam thaj thiab tswj qhov hnyav txuas ntxiv mus.Tom ntej: Bioglutide NA-931 peptidethiab Semaglutide sawv cev rau cov txheej txheem sib txawv, sib txawv hauv cov hom phiaj receptor, xa cov ntaub ntawv, thiab cov haujlwm tshawb fawb. Thaum ob qho tib si ua los ntawm incretin-txoj kev muaj feem cuam tshuam, Semaglutide yog qhov zoo-tsim GLP-1 receptor agonist nrog kev soj ntsuam dav dav, qhov NA-931 tseem yog ib qho kev sim dual-acting molecule nrog dav metabolic signaling peev xwm. Muab piv rau lawv cov qauv molecular, receptor binding affinities, thiab kev coj cwj pwm pharmacological pab cov kws tshawb fawb thiab cov neeg tsim khoom nkag siab tias cov peptides tsim cov teebmeem ntawm lub cev sib txawv thiab qhia txog kev sim tsim thiab kev xaiv cov tswv yim kho mob..
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Cov ntsiav tshuaj
(3) Capsules
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Internal Code: KP-2-6/002
Tom ntej: Bioglutide NA-931
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muabTom ntej: Bioglutide NA-931, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.kpeptide.com/bodybuilding-peptide/bioglutide-na-931.html
Receptor Targets txawv ntawm NA-931 thiab Semaglutide li cas?
Txoj hauv kev uas NA-931 thiab Semaglutide lub hom phiaj receptors yog qhov sib txawv tshwj xeeb ntawm ib leeg thiab muaj kev cuam tshuam tshwj xeeb tshwj xeeb rau cov kev xav tshuaj. Semaglutide ua haujlwm raws li GLP tshwj xeeb -1 receptor agonist, txhais tau tias nws muaj kev sib koom tes nrog thiab nkag siab txog glucagon-zoo li peptide-1 receptor moj khaum. Qhov chaw ib leeg no ua rau nws xav tias yuav cia siab tias yuav ua li cas cov tshuaj yuav ua haujlwm los ntawm cov ntaub ntawv kawm tau zoo uas suav nrog cov kab mob pancreatic beta hlwb, thaiv glucagon, thiab ncua kev tshem tawm plab. Semaglutide tus qauv atomic suav nrog cov kev hloov pauv uas ua rau cov neeg txais kev tso cai zaum kawg ntev dua thiab ruaj khov dua. Rau kev piv txwv, ib qho kev nthuav greasy corrosive saw ua rau nws yooj yim dua rau cov qe dawb los khi thiab ua kom lub cev muaj zog.
NA-931 muaj ntau haiv neeg los ntawm ib leeg- cov phiaj xwm kev kho mob txij li nws cuam tshuam nrog ob lub receptors tib lub sijhawm. Qhov kev tshawb nrhiav peptide no tig rau ob qho tib si GLP-1 thiab glucagon receptors tib lub sijhawm. Qhov no tau teeb tsa qhov kev hloov kho metabolic teeb liab tsim uas cuam tshuam rau ob qho tib si tswj cov piam thaj thiab kev siv lub zog. Lub tswv yim ob lub agonism yog xav kom muab cov txiaj ntsig metabolic uas ua haujlwm ntawm tes. GLP-1 qhov kev txiav txim nce ntxiv affront tawm thiab satiety, whereas glucagon receptor enactment increments ntxiv qabzib tiam tswj nyob rau hauv lub siab thiab vitality siv. Concurring mus nug txog ntawm ob agonist tshuaj, lub tswv yim no tej zaum yuav daws tau metabolic tawg los ntawm kev ua hauj lwm ntawm ob peb physiological daim ntawv nyob rau tib lub sij hawm.
Receptor Affinity thiab Selectivity Profiles
Qhov ceev ntawm cov peptides khi thiab cov receptors tshwj xeeb uas lawv xaiv los khi kom pom qhov sib txawv tseem ceeb. Semaglutide zoo ib yam li tib neeg GLP-1 (kwv yees li 94%), tab sis nws muaj qee qhov kev hloov pauv amino acid uas ua rau nws tsis tshua muaj feem cuam tshuam los ntawm dipeptidyl peptidase-4. Qhov kev npaj no khaws cov kev xaiv GLP-1 receptor thaum ua kom lub neej ib nrab.Tom ntej: Bioglutide NA-931 peptidemuaj cov qauv tsim uas tso cai rau nws kom muaj kev sib npaug sib npaug ntawm GLP-1 thiab glucagon receptors. Qhov no yuav tsum tau ceev faj txog kev tsim vaj tsev molecular kom pom qhov muaj peev xwm ua tau zoo uas txhim kho cov txiaj ntsig metabolic yam tsis muaj glucagon-mediated cuam tshuam ntau dhau. Qhov sib npaug ntawm ob txoj haujlwm receptor no yog qhov tsim qauv tseem ceeb uas cuam tshuam li cas cov tshuaj cuam tshuam rau cov metabolism hauv tag nrho.
Cov kev taw qhia txoj kev qhib los ntawm cov peptides sib txawv raws li cov neeg ua haujlwm receptor. Semaglutide actuates GLP-1-cov cascades tshwj xeeb, nthuav dav cyclic AMP thiab protein kinase A kev ua, uas tswj kev tawm tsam tawm tsam thiab kev qhia zoo. Hauv kev sib txawv, NA-931 xauv hauv ntau cov receptors, tsim kom muaj teeb meem ntau dua uas ua ke GLP-1-tsav anabolic cuam tshuam nrog glucagon-txog catabolic txoj hauv kev. Qhov kev ua ob zaug no tuaj yeem tsim cov tshuaj tiv thaiv metabolic ntau dua li ib leeg-receptor agonists. Xws li kev nyuaj ua rau NA-931 tshwj xeeb tshaj yog muaj txiaj ntsig hauv kev nug txog cov chaw uas sib npaug ntawm ntau txoj hauv kev metabolic yuav tsum tau ua kom muaj kev cuam tshuam zoo rau kev tswj hwm lub cev.
Oral Bioavailability Versus Injectable Delivery Profiles
Kev xa khoom sib txawv tseem ceeb cuam tshuam rau kev tshawb nrhiav cov phiaj xwm thiab daim ntawv thov. Semaglutide tau tsim los ua ib qho kev txhaj tshuaj subcutaneous nrog ib nrab ntev - lub neej txhawb nqa los ntawm cov qe dawb ua haujlwm thiab cov kev hloov pauv uas sawv cev rau kev noj nyiaj txiag. Qhov no txhawb nqa cov tshuaj pharmacokinetics tsis tu ncua thiab kev noj tshuaj tsis txaus ntseeg, tshwj xeeb tshaj yog nyob rau lub lim tiam los ntawm lub lim tiam. Cov ntsiab lus ntawm lo lus semaglutide muaj nyob tab sis xav tau lub koom haum nruj thiab tshwm sim qis dua bioavailability. Cov kev sib piv no qhia txog qhov kev qhia kev thauj mus los cuam tshuam li cas ntawm kev tuav tswj, kev tshawb nrhiav kev tswj xyuas, thiab kev paub zoo, ua rau lub koom haum txheej txheem yog qhov tseem ceeb thaum sib piv peptide ua tiav hauv ob qhov chaw tshawb fawb thiab cov ntsiab lus sib txuas.
Bioglutide NA-931 peptide tau kawm nrog kev tsom mus rau nws qhov muaj peev xwm rau kev xa qhov ncauj, uas yog ib qho teeb meem loj tshaj plaws uas kev kho peptide tseem ntsib. Peptide molecules feem ntau muaj lub sijhawm nyuaj ua bioavailable thaum noj los ntawm qhov ncauj vim tias lawv tau tawg los ntawm cov enzymes hauv lub plab zom mov thiab tsis dhau los ntawm txoj hnyuv epithelium yooj yim. Cov qauv molecular ntawm NA-931 suav nrog cov khoom uas yuav ua rau nws ruaj khov dua hauv kev zom zaub mov thiab ua rau nws yooj yim dua rau cov tshuaj hla cov phab ntsa hauv cov hnyuv. Orally bioavailable peptide tshuaj yog ib kauj ruam loj rau kev kho mob yooj yim dua rau cov neeg mob thiab feem ntau lawv yuav lo nrog nws, tshwj xeeb tshaj yog rau cov kab mob uas xav tau kev tswj xyuas mus sij hawm ntev. Cov kws tshawb fawb tseem tab tom saib mus rau hauv cov thev naus laus zis sib txawv uas tuaj yeem pab nrog qhov ncauj peptide xa. Cov no suav nrog cov enzyme inhibitors, permeation boosters, thiab cov txheej txheem encapsulation.
Pharmacokinetics hloov tag nrho nyob ntawm kev xa tawm tswv yim. Injectable semaglutide qhia tau hais tias ntev ib nrab- lub neej nyob ib ncig ntawm ib lub lis piam, tso cai tsawg koob tshuaj vim muaj kev tuav cia thiab thim rov qab qe dawb tso cai uas ua rau muaj ntau theem. Cov ntsiab lus ntawm kev hais lus tam sim no tsis sib xws los ntawm kev sib piv ntawm assimilation thiab thawj zaug -pass digestion system. Cov khoom no cuam tshuam rau kev siv tshuaj thiab kev tshawb nrhiav kev rov tsim dua tshiab. Rau NA-931, kev nkag siab txog pharmacokinetics yog qhov yooj yim thaum npaj kev xav lossis xaiv cov ntsiab lus. Cov kws tshuaj ntsuam xyuas yuav tsum tau kho cov phiaj xwm kev noj tshuaj thiab cov ntsiab lus txhais nrog rau txhua qhov chaw khaws cia thiab cov yam ntxwv cuam tshuam kom lav tau cov txiaj ntsig tsis tu ncua thiab txhais tau.
Stability thiab peev xwm xav tau sib txawv raws li kev nthuav dav. Kev txhaj tshuaj peptides feem ntau xav tau lub tub yees thiab tswj qhov kub thiab txias kom ua raws li kev xav tau yooj yim ntawm lub peev xwm thiab kev thauj mus los. Cov ntsiab lus ntawm kev hais lus tuaj yeem ua rau muaj kev nplij siab tab sis nyob ntawm kev tiv thaiv kev tsim kho tshiab uas cuam tshuam rau kev ruaj ntseg. Cov txheej txheem suav no cuam tshuam cov kev xaiv tau txais, sim ua haujlwm, thiab kev tswj hwm kev tswj hwm. Rau kev nug txog kev qhia ntawv thiab cov neeg tsim qauv, kev ua kom lub suab sib txuas yog qhov yooj yim los lav qhov kev tshawb nrhiav qhov tseeb thiab kev tsim rov ua dua tshiab, ua rau muaj peev xwm ua tau ib qho kev xav tseem ceeb thaum ua haujlwm nrog peptide-raws li metabolic modulators.
Sib piv Metabolic Signaling Pathways thiab Functional Rows
Semaglutide thiabTom ntej: Bioglutide NA-931 peptidetsim unmistakable metabolic tshwm sim vim qhov sib txawv ntawm receptor tsom rau. Semaglutide tshwj xeeb ua rau GLP-1 receptors, nce qib qabzib- nyob ntawm kev tawm tsam kev tawm tsam, txo qis glucagon qib, ncua kev zom zaub mov, thiab cuam tshuam rau kev xav tau. Cov kev cuam tshuam yooj yim txav mus rau pem hauv ntej kev tswj hwm metabolic los ntawm txoj hauv nruab nrab. Hauv kev sib txawv, NA-931's wider receptor engagement leads to complex signaling intelligent. Qhov kev tsim nyog no qhia txog yuav ua li cas ib lub hom phiaj piv rau ntau lub hom phiaj ua kom zoo li cov kev taw qhia metabolic, tshaj tawm cov kws tshuaj ntsuam xyuas cov cuab yeej tshwj xeeb nyob ntawm seb lawv taw tes rau kev txwv tshwj xeeb lossis xav txog kev tswj hwm cov lus teb metabolic.
Integrated Metabolic Modulation Los ntawm Dual Agonism
NA-931's dual-receptor activation enables integrated metabolic modulation tshaj ib qho -txoj kev cuam tshuam. GLP-1 kev ua haujlwm txhim kho insulin secretion thiab txo qis qab los noj mov, thaum glucagon receptor activation nce kev siv zog thiab txhawb nqa lipid metabolism. Ua ke, cov kev ua no tsim cov teebmeem ntxiv uas cuam tshuam txog ntau yam xwm txheej ntawm cov txheej txheem metabolic. Txoj hauv kev no ua raws li kev tshawb fawb loj hlob ntawm ntau tus receptor agonists, uas yog lub hom phiaj los daws cov teeb meem metabolic uas cuam tshuam nrog ntau txoj hauv kev. NA-931 yog li ua tus qauv tseem ceeb rau kev kawm txog kev sib koom tes receptor ua kom muaj peev xwm cuam tshuam rau tag nrho cov metabolic tshuav nyiaj li cas.
Txoj kev uas cov peptides cuam tshuam rau daim siab metabolism yog nyob ntawm hom receptors lawv khi rau. Semaglutide's GLP-1 qhov kev ua cuam tshuam rau lub siab metabolism hauv txoj kev ncig. Nws ua qhov no los ntawm kev txhim kho cov piam thaj sib npaug thiab txo qis glucagon, uas ua rau txo qis cov piam thaj hauv siab. Los ntawm kev koom tes ncaj qha glucagon receptors, NA-931 xa cov cim ntau ntxiv rau lub siab, uas yuav muaj txiaj ntsig loj dua ntawm cov piam thaj ntau npaum li cas thiab siv cov rog li cas. Thaum glucagon receptors tau qhib, lawv ua kom cov txheej txheem uas hlawv fatty acids. Qhov no tuaj yeem pab tiv thaiv daim siab steatosis los ntawm kev siv cov lipids zoo dua. Cov kev hloov pauv hauv lawv ua haujlwm li cas qhia tias lawv tuaj yeem siv ntau txoj hauv kev hauv kev tshawb fawb uas saib cov metabolism hauv siab, lipid tsis meej, thiab cov piam thaj-lipid sib npaug ua ke.
Adipose ntaub so ntswg thiab lub zog sib npaug cuam tshuam
Ob qho peptides cuam tshuam rau cov ntaub so ntswg adipose thiab lub zog sib npaug tab sis los ntawm cov txheej txheem sib txawv. Semaglutide feem ntau cuam tshuam kev noj qab haus huv los ntawm kev txo qis qab los noj mov, nrog rau cov teebmeem thib ob ntawm adipocytes metabolism. NA-931 ntxiv glucagon-txoj kev sib kho uas yuav ua rau muaj kev siv zog ntxiv los ntawm thermogenesis thiab ua kom cov ntaub so ntswg adipose. Qhov kev cuam tshuam dual no-txo kom tsawg thaum nce kev siv nyiaj-tsim kev hloov pauv ntau dua ntawm lub zog sib npaug. Rau cov kws tshawb fawb, qhov sib txawv no muab cov cuab yeej tseem ceeb rau kev kawm txog kev sib txawv ntawm cov tshuaj hormones tswj cov roj metabolism, thermogenesis, thiab tag nrho lub zog homeostasis.
Lub Sijhawm Kev Ua Haujlwm thiab Kev Sib Tw Sib Nrauj Sib Nqus
Lub sijhawm ua haujlwm yog qhov tseem ceeb cuam tshuam rau kev sim tsim, kev siv tshuaj kho mob, thiab kev ua raws cai. Semaglutide yog tsim los rau kev ua haujlwm txuas ntxiv los ntawm kev hloov pauv amino acid thiab fatty acylation, ua kom muaj zog albumin khi, tiv thaiv DPP-4 degradation, thiab txo lub raum tshem tawm. Cov yam ntxwv no tsim ib nrab ntev - lub neej txhawb nqa ib zaug ib lub lim tiam. Qhov ua tau zoo ntawm cov tshuaj pharmacokinetic profile kom ntseeg tau tias muaj kev ua haujlwm zoo ib yam ntawm lub sijhawm, ua kom yooj yim rau cov tswv yim noj tshuaj thiab txhim kho kev ntseeg siab hauv ob qho tib si kev tshawb fawb thiab kho cov ntsiab lus uas yuav tsum muaj kev cuam tshuam metabolic.
Pharmacokinetic Profiles thiab khov kho -Lub xeev kev txiav txim siab
Lub sij hawm mus txog khov kho- lub xeev txawv heev ntawm cov tebchaw. Semaglutide's ntev ib nrab- lub neej yuav tsum tau txhaj tshuaj ntau dua li ob peb lub lis piam ua ntej cov qib plasma ruaj khov ua tiav, cuam tshuam rau kev kawm ncua sij hawm thiab kev txhais ntawm cov tshuaj pharmacodynamic tag nrho.
luv dua -cov tshuaj sib xyaw ua ke mus txog qhov ruaj khov- xeev nrawm dua tab sis yuav tsum tau txhaj tshuaj ntau dua kom tswj tau qib zoo. Cov kev sib txawv ntawm cov tshuaj pharmacokinetic no cuam tshuam ncaj qha rau kev npaj kev sim, suav nrog cov sijhawm siv tshuaj, cov sijhawm ua piv txwv, thiab kev txheeb xyuas cov ntaub ntawv. Cov kws tshawb fawb yuav tsum ua raws li kev tshawb fawb tsim nrog txhua qhov sib xyaw ua ke ntawm kinetic profile kom paub meej qhov kev ntsuam xyuas ntawm cov lus teb metabolic thiab koob tshuaj - nyob ntawm qhov cuam tshuam.
Qhov cuam tshuam rau Kev Tshawb Fawb Kev Tsim Kho
Lub sij hawm ntawm qhov kev txiav txim siab ua rau kev tshawb fawb raws tu qauv tsim. Luv -cov yeeb yam ua yeeb yam tso cai rau kev kho tshuaj sai sai thiab lub sijhawm ntxuav tawm, ua kom yoog raws thiab sijhawm- kev sim ua tau zoo. Ntev - cov neeg ua yeeb yam xws li semaglutide txo qhov kev siv tshuaj ntau zaus tab sis yuav tsum tau ncua kev kawm ntev los soj ntsuam cov txiaj ntsig siab thiab kev tshem tawm.
Kev xaiv nyob ntawm cov hom phiaj tshawb fawb, seb puas yog tsom rau cov lus teb mob hnyav, kev hloov pauv mus ntev, lossis kev siv tshuaj kom zoo. Rau kev tsim kho tshuaj, lub sijhawm tseem cuam tshuam rau lub hom phiaj cov khoom lag luam thiab kev sib tw ua haujlwm, ua rau nws tseem ceeb
Kev Tshawb Fawb Cov Ntsiab Lus: Ntau -Txoj Kev Ua Haujlwm Zoo Tshaj Plaws Ib Leeg GLP-1 Ua kom pom tseeb
Semaglutide thiabTom ntej: Bioglutide NA-931 peptidepab tshawb fawb lub hom phiaj vim receptor profiles. Semaglutide, nrog zoo -tus yam ntxwv GLP-1 kev ua haujlwm thiab kev kuaj xyuas dav dav, ua haujlwm raws li qhov ntsuas ntsuas hauv kev tshawb fawb metabolic. Nws yog dav siv los kawm GLP-1 receptor biology, ntsuas cov tshuaj incretin-based, thiab sib piv cov tshuaj tshiab. Nws tsim muaj kev nyab xeeb thiab kev ua tau zoo profiles muab kev ntseeg siab rau kev ntsuam xyuas cov txheej txheem tshiab, ua rau nws muaj txiaj ntsig rau ob qho tib si kev tshawb fawb thiab kev tshawb fawb kev txhais lus uas cuam tshuam nrog incretin signaling pathways.
Kev Tshawb Fawb Kev Tshawb Fawb thiab ntau yam -Kev Tshawb Fawb Lub Hom Phiaj
NA-931 yog cov tshuaj tshawb fawb uas tuaj yeem siv rau kev tshawb nrhiav kev tshawb fawb uas saib seb kev tswj cov metabolism ua haujlwm li cas nrog ntau cov receptors. Lub dual agonist profile cia cov kws tshawb fawb saib seb txoj hauv kev zoo sib xws receptor ua haujlwm ua ke los tsim kev sib koom ua ke. Lawv kuj tuaj yeem pom yog tias qhov sib npaug ntau- lub hom phiaj ua kom zoo dua li kev txwv ib leeg-receptor kev koom tes.
Qee qhov chaw tshawb fawb uas zoo rau NA-931 yog cov kev tshawb fawb molecular ntawm kev sib koom ua ke ntawm cov txheej txheem metabolic ua haujlwm, cov tshuaj siv tshuaj sib piv saib ib qho piv rau dual receptor txoj kev, thiab kev txhim kho tshuaj thaum ntxov saib mus rau txoj hauv kev tshiab los kho cov kab mob. Vim hais tias cov molecule no tseem tab tom kawm, nws yuav tsum tau ua tib zoo tsim kev sim thiab ua kom pom tseeb txhawm rau nthuav tawm nws cov kab mob lom neeg tag nrho.
Pharmaceutical Development thiab Translational Research
Cov tuam txhab tsim tshuaj sib txawv saib cov molecules los ntawm cov tswv yim sib txawv ntawm qhov pom. Raws li ib qho zoo-paub cov qauv tshuaj nrog cov txiaj ntsig zoo, semaglutide pab qhia kev tsim cov tshuaj tom ntej - tiam incretin - cov tshuaj. NA-931 yog tus txheej txheem tshiab uas yuav tsum tau ua kom tag nrho cov yam ntxwv ntawm tib neeg ua ntej nws tuaj yeem siv rau tib neeg. Nws kuj yuav tsum tau kuaj xyuas kom muaj kev nyab xeeb thiab ua haujlwm tau zoo.
Formulation optimization, manufacturing scalability, tswj txoj kev npaj, thiab kev sib tw toj roob hauv pes tsom xam yog qee yam uas yuav tsum tau xav txog thaum tsim ib yam khoom tshiab. Cov tuam txhab kev tsim kho tshuaj yuav tsum muaj peev xwm kom tau txais qib siab - kev tshawb fawb zoo- qib peptides los ntawm cov chaw muaj koob npe uas tuaj yeem muab cov ntaub ntawv txheeb xyuas tag nrho, cov khoom zoo sib xws, thiab cov ntaub ntawv txhawb nqa kev tswj hwm.
Xaus
Tom ntej: Bioglutide NA-931 peptidethiab Semaglutide sib txawv heev nyob rau hauv yuav ua li cas lawv lub hom phiaj receptors, yuav ua li cas lawv xa, lawv ua hauj lwm li cas xa metabolic signals, thiab yuav ua li cas lawv siv nyob rau hauv kev kawm. Semaglutide yog ib qho kev xaiv GLP-1 receptor agonist uas tau siv ntau hauv kev sim tshuaj. Ntawm qhov tod tes, NA-931 tseem tab tom kawm ua dual GLP-1 / glucagon receptor agonist uas tab tom nrhiav rau kev hloov ntau lub hom phiaj metabolic. Cov kev sib txawv no suav nrog cov txheej txheem molecular, cov yam ntxwv ntawm lub cev, thiab cov teeb meem ua tau zoo uas cuam tshuam txog kev sim npaj thiab tsim cov tshuaj li cas.
Cov kws tshawb fawb, kws tsim tshuaj, thiab kws kho mob tuaj yeem txiav txim siab zoo dua thaum xaiv cov tshuaj peptide rau kev siv sib txawv thaum lawv nkag siab qhov sib txawv no. Txawm hais tias ib leeg - lub hom phiaj xaiv los yog ntau - kev sib koom ua ke receptor yog siv los ntawm kev kawm cov hom phiaj, xws li saib mus rau hauv qhov zoo- cov txheej txheem paub lossis txoj hauv kev tshiab los kho cov kab mob. Ob qho tshuaj no muaj txiaj ntsig zoo rau kev tshawb fawb metabolic, thiab lawv txhua tus muaj lawv tus kheej cov txiaj ntsig uas ua rau lawv zoo dua rau ntau hom kev tshawb fawb thiab kev tsim kho.
FAQ
1. Dab tsi yog qhov txawv ntawm NA-931 thiab Semaglutide?
+
-
Cov kev hloov pauv tseem ceeb hauv cov qauv yuav tsum ua nrog lawv cov hom phiaj tsim qauv molecular thiab cov receptors lawv tau tsom rau. Semaglutide muaj cov amino acids sib txawv ntawm txoj haujlwm 8 thiab 34 piv rau haiv neeg GLP-1. Nws kuj tseem muaj qhov txuas ntxiv fatty acid txuas los ntawm qhov sib txawv ntawm txoj hauj lwm 26, uas cia albumin koom nrog thiab muab nws ib nrab-lub neej ntev. NA-931 muaj ib feem ntawm nws cov qauv uas yog npaj los khi rau ob qho tib si GLP-1 thiab glucagon receptors nrog lub zog sib npaug. Qhov no yuav tsum muaj cov qauv tshuaj tshwj xeeb uas tuaj yeem tswj kev khi rau ob qho tib si receptors thaum ua kom muaj qhov sib npaug potency. Cov kev hloov pauv hauv cov qauv no muaj kev cuam tshuam ncaj qha rau cov txheej txheem metabolic, receptor tshwj xeeb, thiab pharmacokinetics.
2. Yuav ua li cas cov kev xa khoom sib txawv cuam tshuam rau cov ntawv thov tshawb fawb?
+
-
Cov txheej txheem ntawm kev xa khoom muaj txiaj ntsig zoo rau kev tsim qauv ntawm kev tshawb fawb, kev soj ntsuam pharmacokinetic, thiab cov ntsiab lus tseeb ntawm qhov kev sim. Nws yooj yim dua los ua cov qauv tshuaj pharmacokinetic thiab kev tshawb fawb txog kev ua tau zoo nrog cov tshuaj txhaj tshuaj vim tias lawv muaj cov bioavailability zoo ib yam thiab koob tshuaj - teb kev sib raug zoo. Kev xa hauv qhov ncauj ntxiv ntau yam uas yuav tsum tau txhais thiab tswj hwm, xws li kev hloov pauv hauv kev nqus, ua ntej - dhau cov metabolism, thiab kev sib cuam tshuam ntawm cov khoom noj. Rau kev siv tshuaj yooj yim, cov kev tshawb fawb saib ntev - cov teebmeem metabolic tej zaum yuav nyiam txuas ntxiv - ncua sij hawm txhaj tshuaj. Ntawm qhov tod tes, kev tshawb fawb saib rau hauv cov txheej txheem plab hnyuv lossis qhov ncauj bioavailability xav tau cov tshuaj uas tau noj los ntawm qhov ncauj. Kev xaiv yog nyob ntawm lub hom phiaj ntawm txoj kev tshawb fawb thiab cov kev xav tau ntawm kev sim tsim.
3. Cov ntaub ntawv txheeb xyuas dab tsi yuav tsum nrog rau kev tshawb fawb -qib peptides?
+
-
Rau kev tshawb fawb -qib peptides, tag nrho cov ntaub ntawv tshuaj ntsuam xyuas yuav tsum suav nrog Daim Ntawv Pov Thawj Kev Ntsuam Xyuas uas lees paub cov peptides kev txheeb xyuas, purity, thiab cov ntsiab lus siv ntau txoj kev sib txawv, xws li HPLC, huab hwm coj spectrometry, thiab amino acid tsom xam. Cov ntaub ntawv ruaj khov nyob rau hauv qee yam kev khaws cia, kev tshuaj xyuas cov kua dej tshuav, cov txiaj ntsig kuaj microbial, thiab qib endotoxin thaum cuam tshuam yog qee cov ntaub ntawv tseem ceeb uas yuav tsum tau khaws cia. Kev tswj hwm kev xa tawm thiab kev tswj hwm kev tswj hwm zoo yog pab los ntawm kev tsim cov ntaub ntawv xws li cov ntaub ntawv khaws tseg, cov txheej txheem tswj kom zoo, thiab cov ntaub ntawv ua raws GMP. Cov neeg muag khoom ntseeg tau muab tag nrho kev txheeb xyuas tus yam ntxwv, uas tso cai rau koj npaj kev sim nrog kev ntseeg siab thiab ua raws li cov cai.
Vim li cas thiaj xaiv BLOOM TECH li koj Bioglutide NA-931 Peptide Supplier?
Cov pab pawg tshawb fawb thiab cov tuam txhab tshuaj xav tau ntau tshaj li cov khoom lag luam thaum lawv xaiv ib qhoTom ntej: Bioglutide NA-931 peptidetus neeg muag khoom. Nrog GMP-cov chaw tsim khoom tau ntawv pov thawj uas tau pom zoo los ntawm US-FDA, EU, JP, thiab CFDA, BLOOM TECH muaj kev txhawb nqa tag nrho thoob plaws koj txoj kev tshawb fawb thiab kev txhim kho. Peb txoj kev lees paub zoo siv peb theem ntawm kev tshawb fawb tshawb fawb kom paub tseeb tias txhua pawg ua tau raws li koj qhov yuav tsum tau ua. Yog tias vim li cas cov khoom lag luam tsis ua raws li koj cov qauv, koj tuaj yeem tau txais koj cov nyiaj rov qab tag nrho. Ntxiv nrog rau qhov ua tau zoo, peb muab cov nqi tsim nyog nrog cov qauv tsim qauv, raug coj ua raws sijhawm los ntawm peb cov kev sib koom ua ke ERP platform, thiab tag nrho cov ntaub ntawv raug cai los txhawb koj cov kev tshawb fawb thiab kev txhim kho. Peb pab pawg kws tshaj lij tuaj yeem ua tau txhua yam, txij li me me - nplai synthesis hauv chav kuaj mus rau ntau lawm, thiab lawv paub yuav ua li cas kom tau raws li cov kev xav tau tshwj xeeb ntawm cov tshuaj nruab nrab thiab kev tshawb fawb - qib peptides. BLOOM TECH muab cov khoom lag luam zoo nrog cov kev pabcuam uas tsom mus rau cov neeg siv khoom, txawm tias koj xav tau kev txheeb xyuas tus yam ntxwv zoo, kev tsim cov khoom siv, lossis kev tswj xyuas cov saw hlau txhim khu kev qha. Email peb pab neeg muag khoom ntawmSales@bloomtechz.comtham txog koj cov kev xav tau tshwj xeeb thiab nrhiav seb peb txoj kev paub txog cov organic synthesis thiab cov tshuaj intermediates tuaj yeem pab ua kom koj cov haujlwm tshawb fawb metabolic.
Cov ntaub ntawv
1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-zoo li Peptide-1. Cell Metabolism. 2018;27(4):740-756.
2. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 Receptor Agonists hauv Kev Kho Mob Ntshav Qab Zib Hom 2: Lub Xeev- ntawm -the-Art. Molecular Metabolism. 2021; 46:101102.
3. Finan B, Yang B, Ottaway N, Müller TD. Targeted Estrogen Delivery Reverses Metabolic Syndrome. Nature Medicine. 2012;18(12):1847-1856.
4. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J. Discovery of the One -Txhua Lub Limtiam Glucagon-Zoo li Peptide-1 Analogue Semaglutide. Phau ntawv Journal of Medicinal Chemistry. 2015;58(18): 7370-7380.
5. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR. Glucagon-zoo li Peptide 1 (GLP-1). Molecular Metabolism. 2019; 30:72-130.
6. Hnub JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J. A New Glucagon thiab GLP-1 Co-Agonist Eliminates Obesity in Rodents. Nature Chemical Biology. 2009;5(10):749-757.
